Related Experiment Video

Updated: May 3, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.8K

New HER2-positive targeting agents in clinical practice

Sara Tolaney1

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Yawkey 1257, Boston, MA, 02215, USA, stolaney@partners.org.

Current Oncology Reports
|January 21, 2014
PubMed

Insights

Human epidermal growth factor receptor 2 (HER2)-positive breast cancer treatment has advanced with new drugs, but resistance remains a challenge. Optimizing the sequencing and combination of these HER2-targeted agents is crucial for improving patient outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Overexpression of human epidermal growth factor receptor 2 (HER2) occurs in 20-25% of invasive breast cancers, correlating with poor prognosis.
  • Trastuzumab, a HER2-targeted therapy, significantly improved outcomes but acquired resistance is a common clinical problem.
  • Despite advances, challenges persist in managing HER2-positive metastatic breast cancer, particularly regarding treatment resistance.

Purpose of the Study:

  • To review the current landscape of HER2-targeted therapies for breast cancer.
  • To discuss the mechanisms of resistance to HER2-targeted agents.
  • To explore strategies for optimizing the sequencing and combination of HER2-targeted agents.

Main Methods:

  • Literature review of clinical trials and preclinical studies on HER2-targeted therapies.
  • Analysis of resistance mechanisms to HER2-targeted agents.
  • Discussion of emerging HER2-targeted drugs and treatment paradigms.

Main Results:

  • Several newer anti-HER2 agents, including lapatinib, pertuzumab, and trastuzumab emtansine, have been developed.
  • Understanding resistance mechanisms is key to developing effective treatment strategies.
  • Optimal sequencing and combination of HER2-targeted agents are critical for overcoming resistance.

Conclusions:

  • Advances in HER2-targeted therapies offer new hope for patients with HER2-positive breast cancer.
  • Addressing treatment resistance through novel drug development and strategic combinations is essential.
  • Further research is needed to establish optimal treatment sequences for maximizing patient benefit.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

4.9K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
820